










Validation of Clinical Testing for Warfarin Sensitivity
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Responses to warfarin (Coumadin) anticoagulation
therapy are affected by genetic variability in both the
CYP2C9 and VKORC1 genes. Validation of pharmaco-
genetic testing for warfarin responses includes dem-
onstration of analytical validity of testing platforms
and of the clinical validity of testing. We compared
four platforms for determining the relevant single
nucleotide polymorphisms (SNPs) in both CYP2C9
and VKORC1 that are associated with warfarin sensi-
tivity (Third Wave Invader Plus, ParagonDx/Cepheid
Smart Cycler, Idaho Technology LightCycler, and Au-
toGenomics Infiniti). Each method was examined for
accuracy, cost, and turnaround time. All genotyping
methods demonstrated greater than 95% accuracy for
identifying the relevant SNPs (CYP2C9 *2 and *3;
VKORC1 1639 or 1173). The ParagonDx and Idaho
Technology assays had the shortest turnaround and
hands-on times. The Third Wave assay was readily
scalable to higher test volumes but had the longest
hands-on time. The AutoGenomics assay interrogated
the largest number of SNPs but had the longest turn-
around time. Four published warfarin-dosing algo-
rithms (Washington University, UCSF, Louisville, and
Newcastle) were compared for accuracy for predict-
ing warfarin dose in a retrospective analysis of a local
patient population on long-term, stable warfarin
therapy. The predicted doses from both the Washing-
ton University and UCSF algorithms demonstrated the
best correlation with actual warfarin doses. (J Mol
Diagn 2009, 11:216–225; DOI: 10.2353/jmoldx.2009.080123)
In 2007, the US Food and Drug Administration modified
the package insert for warfarin (Coumadin) to include
information on the relationship of safe and effective dos-
age to specific single nucleotide polymorphisms (SNPs)
in two genes, cytochrome P450 2C9 (CYP2C9) and vita-
min K epoxide reductase complex subunit 1 (VKORC1).
Warfarin binds to and inhibits vitamin K epoxide reduc-
tase (VKOR), encoded by VKORC1, thereby inhibiting
activation of vitamin K-dependent clotting factors. A sin-
gle common VKORC1 SNP 1639/3673 AG defines
VKORC1 haplotypes with increased sensitivity to warfarin
(group A haplotypes, H1 and H2).1–9 CYP2C9 is respon-
sible for metabolism of 90% of S-warfarin, the more
active enantiomer of warfarin. Two common allelic
variants of CYP2C9 with reduced enzymatic activity
(CYP2C9*2 and CYP2C9*3) have been associated with
reduced metabolism of warfarin, lower required doses of
warfarin to achieve adequate anticoagulation, and in-
creased risk of adverse events when beginning warfarin
therapy.10–12
As a result of increased awareness of the impact of
these SNPs on warfarin dosage, it is likely that clinical
laboratories will increasingly be asked to provide geno-
type information for the above genes. Thus, there is a
need to evaluate both the analytic and clinical validity of
genotyping to make dosing recommendations for warfa-
rin. Several assays for genotyping are now commercially
available. We evaluated four platforms for determining
relevant SNPs in CYP2C9 and VKORC1: the Third Wave
Invader Plus CYP2C9 and VKORC1 reagents, the Ce-
pheid SmartCycler Rapid Genotyping Assay for CYP2C9
and VKORC1 (developed by ParagonDx), the Idaho
Technology Warfarin Genotyping Reagents on the Roche
LightCycler and the AutoGenomics Infiniti 2C9-VKORC1
assay (now marketed as Warfarin XP).
Several different dosing algorithms have been devised
that incorporate VKORC1 and CYP2C9 genotype, in ad-
dition to demographic and clinical information, to predict
optimal warfarin dose. We compared the accuracy of four
published algorithms for determining warfarin dosage,
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herein called Wash U,13 UCSF,14 Louisville,15 and New-
castle,16 using retrospective data from a local patient
population on long-term, stable warfarin therapy.
Materials and Methods
DNA Samples
Residual DNA from patients on warfarin therapy was
generously provided by Darryl Stafford’s laboratory
(University of North Carolina). These samples were pre-
viously genotyped for SNPs in the CYP2C9 and VKORC1
genes using a combination of DNA sequencing and SNP
genotyping by real-time polymerase chain reaction
(PCR).6 We selected 20 samples that had a variety of
combinations of SNPs at the sites to be genotyped to
assess the accuracy of each platform for testing various
genotype combinations. Each sample was analyzed by
each method separately, following the manufacturer’s
instructions.
Genotyping Analysis
Four genotyping platforms were compared for CYP2C9
and VKORC1 genotyping: Invader Plus CYP2C9 and
VKORC1 analyte-specific reagents from Third Wave
Technologies (a subsidiary of Hologic, Inc., Madison,
WI); Warfarin SimpleProbe Genotyping Reagents from
Idaho Technology, Inc. (Salt Lake City, UT); Infiniti War-
farin XP Assay from AutoGenomics, Inc. (Carlsbad, CA);
and the SmartCycler Rapid Genotyping Assay for
CYP2C9 and VKORC1, developed by ParagonDx (Mor-
risville, NC). Reagents and instrumentation for analysis
were provided by the manufacturers.
The 20 residual DNA samples were analyzed on each
platform. Genotype information was compared for each
of the SNPs that are included on more than one platform:
CYP2C9 *2 and *3, and VKORC1 1639 (3673) and 3730
(9041). The SNPs detected by each assay are listed in
Table 1. Because VKORC1 1639 (3673) has been
shown to be in complete linkage disequilibrium with
VKORC1 1173(6484),1 the presence of either SNP was
denoted as VKORC1 1639 for comparison. Each assay
was run at least three times with a batch of six samples
plus three controls (blank, CYP2C9 *2/*3, and VKORC1
1639A/G) to represent a projected typical clinical run.
Hands-on time was recorded using a stopwatch at each
step for each assay and totaled for comparison.
Third Wave Invader Plus Assay
The Third Wave Invader Plus assay was performed per
manufacturer instructions with an 18-cycle multiplex PCR
on a PE9700 thermal cycler (Applied Biosystems, Foster
City, CA), with the resultant amplicons used in three sepa-
rate Invader reactions, one each for CYP2C9 *2 and *3 and
VKORC1 1639. Fluorescence related to both wild-type (ref-
erence) sequence and SNP was measured in each well by a
GENios FL plate reader (Tecan, San Jose, CA) and the results
loaded into an Excel spreadsheet provided by the company.
ParagonDx/Cepheid assay
The ParagonDx/Cepheid CYP2C9/VKORC1 research use
only (RUO) assay was performed per manufacturer in-
structions using two multiplex master mixes, each con-
taining four primer sets and probes that were resus-
pended from lyophilized beads, one for CYP2C9 *2 and
*3 and the other for VKORC1 1173 and 3730. Real-time
PCR analysis was performed on the SmartCycler (Ce-
pheid, Sunnyvale, CA) and the results loaded into an
Excel-based interpretation file provided by ParagonDx
(formerly Gentris). A Food and Drug Administration
cleared version of this assay without the VKORC1 3730
SNP is to be marketed by Cepheid but is not yet com-
mercially available at the time of this publication.
Idaho Technology LightCycler Assay
The Idaho Technology SimpleProbe Warfarin assay was
performed per manufacturer instructions. Reactions for
each SNP tested (CYP2C9 *2 and *3 and VKORC1 1639
A/G) were analyzed simultaneously on a Roche LightCy-
cler in separate capillaries and melting curves were eval-
uated for each sample. The assay can also be performed
using a LightScanner (Idaho Technology) or other instru-
ment for melting curve analysis. The primers are de-
signed to match each SNP, so that the reference or
wild-type sequence is an imperfect match and has a
lower melting temperature.
AutoGenomics Warfarin XP Assay
The AutoGenomics Warfarin XP assay was performed per
manufacturer instructions with a single multiplex PCR on
a PE9700 thermal cycler, followed by allele-specific
primer extension, hybridization and detection performed
Table 1. SNPs Detected by Each Assay
Assay CYP2C9 SNPs VKORC1 SNPs
Third Wave Invader Plus *2,*3 1639G/A
ParagonDx/SmartCycler *2,*3 1173C/T, 3730G/A
Idaho Technology/LightCycler *2,*3 1639G/A
AutoGenomics Infiniti *2,*3,*4,*5,*6,*11 1639G/A, 497T/G, 698C/T, 1173C/T, 1542G/C,
2255C/T, 3462C/T, 3730G/A
Note: 1639GA and 1173CT are in 100% linkage disequilibrium (see Table 2).
Warfarin Genotyping Evaluation 217
JMD May 2009, Vol. 11, No. 3
on the automated Infiniti instrument (AutoGenomics). The
extended primers, incorporating Cy3-labeled dCTPs, are
hybridized to chips using the AutoGenomics ZipCode-
anti-ZipCode technology, and fluorescence at each set of
the SNP-specific sites is read by the onboard confocal
microscope. Onboard software analyzes the raw data,
reports fluorescence values for both alleles at each of 14
SNPs (Table 1), and reports SNP determination. AutoG-
enomics also markets a Food and Drug Administration
approved Infiniti Warfarin assay, which detects only
CYP2C9 *2 and *3 and VKORC1 1639 (3673), that was
not analyzed in this comparison study.
DNA Sequencing
Selected samples from patients on high doses of warfarin were
subjected to dideoxy sequencing of the promoter and coding
regions of the VKORC1 gene and capillary electrophoresis on
an Applied Biosystems 3130xl genetic analyzer.
Dosing Algorithm Evaluation
Patients treated at the University of North Carolina antico-
agulation clinic who were on long-term, stable warfarin ther-
apy were retrospectively analyzed for the accuracy of the
dosing algorithms to predict stable warfarin dose. VKORC1
and CYP2C9 genotype and clinical information were avail-
able from a previous study.6 VKORC1 1173 (6484) geno-
type was assumed to be in complete linkage disequilibrium
with VKORC1 1639 (3673).1 Additional patient data nec-
essary for each of the dosing algorithms were acquired
through chart review, with appropriate informed consent
per University of North Carolina Institutional Review Board
approval. Sufficient information for all of the algorithms was
available on 75 patients (81% Caucasian, 19% African-
American; 63% male, 37% female). The required data for
each of the 75 patients was entered into each algorithm and
the recommended warfarin dosage calculated.
For the Wash U algorithm, data for initial warfarin
dose calculation was input on the website http://www.
warfarindosing.org (last accessed July 21, 2008). For the
UCSF, Louisville, and Newcastle algorithms, an Excel
spreadsheet was devised to calculate dose using pub-
lished equations.14–16 The Newcastle algorithm incorpo-
rates age, height, the VKORC1 1639 (3673) SNP, and
CYP2C9 *2 and *3. The other algorithms include the same
genetic variables plus additional variables. The Louisville
algorithm incorporates age, gender, and weight instead of
height. The Wash U algorithm incorporates age, body sur-
face area, ethnicity, target international normalized ratio
(INR), history of smoking, clinical indication for warfarin, and
the presence of other medications that can affect warfarin
metabolism (amiodarone). The UCSF algorithm includes
the VKORC1 2255 (7566) SNP in addition to the genetic
variants included in the other algorithms, along with
age, height, weight, gender, ethnicity, history of smok-
ing, and the presence of medications that can affect
warfarin metabolism (amiodarone or sulfamethoxazole).
Actual dose for each patient was determined as the
mean of the last five doses of warfarin on reaching target
prothrombin time INR. The calculated recommended
dose from each algorithm was plotted against each pa-
tient’s actual dose in an XY scatter plot using Microsoft
(Redmond, WA) Excel 2000 (version 9.0.3821 SR-1). A
best-fit trendline, correlation coefficient (r), and coeffi-
cient of determination (r2) were determined by linear
regression using Excel. The Excel linear regression cal-
culations for the best-fit trendline are as follows: m 
n(xy)  xy/n(x2)  (x)2; b  y  mx/n; r 
n(xy)  xy/[n(x2)  (x)2] [n(y2)  (y)2], where
n is the number of data points, m is the slope, b is the
y-intercept, and r is the correlation coefficient.
Results
Genotyping Method Comparison
The SNPs detected by each assay are listed in Table 1.
All of the methods evaluated detect CYP2C9 *2 and *3
and at least one of the relevant VKORC1 SNPs, 1639
(3673) GA or 1173 (6484) CT. These two VKORC1
SNPs are in 100% linkage disequilibrium and are both
associated with increased sensitivity to warfarin. The
ParagonDx and AutoGenomics assays also detect
VKORC1 3730(9041) GA, which is present in group B
VKORC1 haplotypes H7 and H8 and has been associ-
ated with higher dosage requirements of warfarin.1,6 The
AutoGenomics Warfarin XP detects six CYP2C9 variants
associated with reduced metabolism and eight VKORC1
SNPs, which enables determination of nine described
VKORC1 haplotypes (Table 2).
Data compiled for turnaround time (TAT) and hands-on
time for each assay are shown in Table 3. The figures are
based on actual time during setup and analysis of a run
consisting of six samples and three controls. The Para-
gonDx and Idaho Technology assays had the lowest
hands-on time and TAT because data are collected dur-
ing or immediately after PCR onboard the instrument. The
AutoGenomics required less than 1 hour of hands-on
time because the allele-specific primer extension, hybrid-
ization, and detection are all automated, but had a longer
TAT. The TAT increases with the number of samples be-
cause of sequential analysis by the Infiniti instrument. The
Third Wave assay required the most labor because of the
manipulations after PCR required for the Invader assay, but
the rapidity of its detection method gave it a significantly
shorter TAT than the AutoGenomics assay. Reagent list
prices and instrument costs are compared in Table 3.
A summary of genotype results for the 20 previously
characterized samples is shown in Table 4. The table in-
cludes data for each SNP that is interrogated by more than
one of the assays evaluated (CYP2C9 *2 and *3; VKORC1
1639AG or 1173CT and VKORC1 3730GA). For
comparison, results for the VKORC1 SNPs 1639AG
and 1173CT, which are in complete linkage disequilib-
rium, are reported as VKORC1 1639. Some samples
were not tested at all SNPs with every assay because of
limited availability of reagents. Each assay demonstrated
100% accuracy, with the exception of the AutoGenomics
assay, which gave one indeterminate result for CYP2C9
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(95% accuracy). The accuracy of the AutoGenomics as-
say for genotyping additional SNPs in VKORC1 was also
examined for the 20 samples by correlation with previous
results for SNPs 497 (5808) T/G, 698 (6009) C/T, 1542
(6853) C/G, and 2255 (7566) T/C,6 and demonstrated
100% accuracy (data not shown).
The advantages and disadvantages of each assay are
summarized in Table 5. The technically simplest assays
were the Idaho Technology and ParagonDx assays be-
cause they use established, one-tube methods. The Third
Wave Invader Plus assay required more manipulation in
transferring the PCR products into the Invader reaction and
then into the fluorometer. The AutoGenomics is a relatively
new instrument and uses novel technology, which required
specialized training. Capital instrumentation requirements
differ for each of the assays. The Third Wave assay requires
only a fluorometer, the ParagonDx requires a Cepheid
SmartCycler, and the Idaho Technology assay requires a
Roche LightCycler 2.0 or another melting curve analysis
instrument. The largest capital investment requirement is
the Infiniti instrument from AutoGenomics.
Dosing Algorithm Comparison
A comparison of the four algorithms for determining war-
farin dosage is shown in Figure 1. The Wash U algorithm
requires more clinical information than the other three,
which limited the number of patients we were able to
analyze in this retrospective study. Only those patients for
whom all four algorithms could be run were included in
the analysis (n  75). Overall, the subpopulation of pa-
tients for which we were able to run the algorithms was
similar demographically and genotypically to the total
study population (n  117)6 and therefore it is unlikely
that the data are biased toward any particular group (see
Supplemental Table S1 at http://jmd.amjpathol.org). The
study population is similar demographically to the total
patient population followed at the University of North
Carolina. The recommended dosage from the Wash U
and UCSF algorithms had the best correlation with stable
dosage in the patient population, with correlation coeffi-
cients (r) of 0.60 compared with 0.58 for the Louisville
algorithm and 0.48 for the Newcastle algorithm. The dif-
ference between the Wash U, UCSF, and Louisville algo-
rithms is not significant, whereas the Newcastle algorithm
was significantly less predictive of stable dose. The Lou-
isville algorithm calculated a high warfarin dose of
greater than 12 mg/day for two patients whose actual
warfarin dose was less than 9 mg/day.
Two of the patients had much higher actual warfarin
doses than predicted by any of the algorithms (Figure 1,
square symbols). Both of these outlier patients were
African-American females with an actual stable warfarin
dose of 12 mg/day. Removal of these two data points
improved the correlation coefficient for each algorithm,
particularly the Wash U and UCSF algorithms (r  0.67)
(Table 6). All four algorithms performed less well among
the African-American population, even after removal of
the outlier patients (Table 7). However, the sample size
was too small (n  14) to make conclusions about the
efficacy of the dosing algorithms in this population.
For the two outlier patients, sequencing of the coding
region of VKORC1 was performed to examine for muta-
tions, and previously performed SNP analysis6 was ex-







sample (list price)† Instrumentation required
Equipment cost
(approximate)‡
Third Wave Invader 3.2 1.42 $55.00 Thermal cycler, 96-well fluorometer $12,000
ParagonDx/Cepheid 1.5 0.75 Not available§ Cepheid SmartCycler $34,000
Idaho Technology 2 0.75 $12.00 Roche LightCycler $40,000
AutoGenomics 10.6 0.83 $75.00 Thermal cycler, Infiniti analyzer $125,000
* Figures are based on a run of six patient samples and three controls; DNA extraction time not included.
† Cost does not include DNA extraction costs, polymerase enzyme, or disposables.
‡ Cost of thermal cycler when required not included.
§ The ParagonDx/Cepheid assay is not commercially available at this time.






















H1 C C A T C T C T C G
H2 C C A G C T C T C G
H3 C C G T C C C C C G
H4 C C G T C C G T C G
H5 T C A G C T C T C G
H6 T C G T C C G C C G
H7 T C G T C C G C C A
H7* T C G T C C G C T A
H8 T A G T C C G C C A
H9 T A G T T C G C C G
Shown is the VKORC1 sequence at each of the SNPs shown for each haplotype. The VKORC1 H7* haplotype is a subset of haplotype H7 with the
3462(8773) CT SNP. SNPs in bold are typed by the AutoGenomics Warfarin XP assay. AutoGenomics cannot differentiate H2 versus H5 (can haplotype all
others). Haplotypes H1 and H2 (group A) are associated with lower doses of warfarin; haplotypes H7 to H9 (group B) with higher doses.1,14
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amined to determine VKORC1 haplotypes. The first pa-
tient had an actual mean warfarin dose of 17.4 mg/day.
This individual was CYP2C9 *1/*1 (wild type) and had
VKORC1 SNPs 2255 (7566) C/T and 3730 (9041) G/A,
indicating that the patient is heterozygous for VKORC1
haplotype H4 and a group B haplotype (H7 or H8). The
VKORC1 2255CT SNP is seen in group A haplotypes,
which are associated with increased warfarin sensitivity, as
well as in haplotype H4, a less common haplotype for which
there is little information on warfarin dose correlation. The
3730 GA SNP is associated with group B haplotypes,
which have been correlated with higher warfarin doses,1,5
but it is not included in any of the dosing algorithms. In
addition, DNA sequencing demonstrated a novel single
nucleotide change in the promoter, VKORC1 477 (4835)
G/A, which to our knowledge has not been published pre-
viously. The impact of this novel change is unknown.
The second outlier patient had an actual mean warfarin
dose of 13.8 mg/day. This individual was also CYP2C9
*1/*1 and was heterozygous for VKORC1 1639 (3673)
G/A, 1173 (6484) C/T, and 2255 (7566) C/T and homozy-
gous for 1542 (6853) C/C (VKORC1 haplotypes H1/H3).
Haplotype H1 is a group A haplotype associated with
increased sensitivity to warfarin. Haplotype H3 is a less
common haplotype with little information on warfarin dose
correlation. No VKORC1 coding region mutations were
found by DNA sequencing and chart review revealed
nothing remarkable that could account for the high war-
farin dose requirement in either patient.
Discussion
Warfarin is one of the most commonly prescribed medi-
cations in the U.S. Because of its narrow therapeutic
range and the wide variation in warfarin dose requirement
in different individuals, there is a significant risk of bleed-
ing or thromboembolic events during warfarin therapy.
Table 4. CYP2C9 and VKORC1 Genotyping Results
CYP2C9 VKORC1
Sample Third Wave Idaho Tech ParagonDx AutoGenomics Third Wave* Idaho Tech* ParagonDx† AutoGenomics
01 *3/*3 *3/*3 *3/*3 *3/*3 1639/1639 1639/1639 1639/1639 1639/1639
02 wt/wt wt/wt ND wt/wt wt/wt wt/wt 3730/3730 3730/3730
03 *2/wt *2/wt *2/wt *2/wt wt/wt wt/wt ND 3730/3730
04 wt/wt wt/wt wt/wt wt/wt wt/wt wt/wt ND 3730/wt
05 wt/wt wt/wt ND wt/wt 1639/wt 1639/wt 1639/wt 1639/wt
06 *2/wt *2/wt *2/wt IND 1639/1639 1639/1639 ND 1639/1639
07 *3/wt *3/wt *3/wt *3/wt 1639/wt 1639/wt 1639/wt 1639/wt
08 wt/wt wt/wt ND wt/wt 1639/wt 1639/wt 1639/3730 1639/3730
09 *3/wt *3/wt *3/wt *3/wt 1639/wt 1639/wt 1639/3730 1639/3730
10 *2/wt *2/wt *2/wt *2/wt 1639/1639 1639/1639 ND 1639/1639
11 wt/wt wt/wt ND wt/wt wt/wt wt/wt 3730/3730 3730/3730
12 *2/*3 *2/*3 *2/*3 *2/*3 1639/wt 1639/wt 1639/3730 1639/3730
13 wt/wt wt/wt ND wt/wt 1639/1639 1639/1639 1639/1639 1639/1639
14 *2/wt *2/wt ND *2/wt wt/wt wt/wt 3730/3730 3730/3730
15 wt/wt wt/wt ND wt/wt wt/wt wt/wt 3730/3730 3730/3730
16 wt/wt wt/wt ND wt/wt 1639/1639 1639/1639 1639/1639 1639/1639
17 *3/wt *3/wt *3/wt *3/wt 1639/wt 1639/wt ND 1639/3730
18 wt/wt wt/wt ND wt/wt wt/wt wt/wt 3730/wt 3730/wt
19 *2/wt *2/wt *2/wt *2/wt 1639/wt 1639/wt ND 1639/3730
20 wt/wt wt/wt wt/wt wt/wt 1639/1639 1639/1639 1639/1639 1639/1639
Accuracy 100% 100% 100% 95% 100% 100% 100% 100%
1639  VKORC1 SNP 1639 (3673) GA. 3730  VKORC1 SNP 3730 (9041) GA.
* Method does not genotype VKORC1 3730.
† ParagonDx method genotypes VKORC1 1173, reported here as 1639 assuming 100% LD for clarity. ND, sample not tested at this locus
because of limited reagents available at the time of testing. IND, indeterminate results, sample inadequate to repeat. wt, wild type. All results were
confirmed by sequencing or SNP analysis.6
Table 5. Advantages and Disadvantages of Each Method
Method Advantages Disadvantages
Third Wave Invader Low capital expense Post-PCR manipulations
Established methodology Hands-on time
Readily scalable to larger run sizes
ParagonDx/Cepheid SmartCycler Short TAT Not commercially available
Ease of use Capital investment
Established methodology Small run size
Low hands-on time




AutoGenomics Infiniti Number of SNPs offered Long TAT
Warfarin XP Post-PCR automated Large capital investment
Easily adaptable to include additional SNPs Less established methodology
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The recent understanding that genetic variability in
CYP2C9 and VKORC1 can account for some of the vari-
ability in individual warfarin dose requirements has
prompted the development of commercially available
genotyping assays and of dosing algorithms that incor-
porate genotype information. We compared four different
analysis platforms and four dosing algorithms for deter-
mining warfarin dosage in a local patient population.
Genotyping Test Platforms
All four platforms performed well and gave accurate
genotyping results. The selection of genotyping platform
must take into consideration needs, demands, and avail-
able resources of each clinical laboratory. Although the
Idaho Technology and ParagonDx methods have the
shortest TAT and hands-on time of the four, the additional
SNPs available on the AutoGenomics Infiniti may be valu-
able in collecting data in non-Caucasian patients and
those with less common genotypes. The Third Wave as-
say offers comparable TAT and the advantages of low
capital equipment investment and scalability to medium
test volumes. Although most of the platforms demon-
strated 100% accuracy, the AutoGenomics assay gave
one indeterminate result for CYP2C9. In our experience,
indeterminate results on the AutoGenomics assay are
usually resolved with repeat testing. A recent publica-
tion compared two of these platforms plus two different
2C9-VKOR genotyping platforms and also found very
good genotyping accuracy by each of the commercial
platforms.17
TAT may be a crucial factor for warfarin genotyping
and for pharmacogenomic (PGx) testing in general. Many
of the adverse events associated with warfarin occur
during the initiation period. Ideally, genetic variability that
affects drug response would be known before drug ad-
ministration. This may not always be feasible for drugs
such as warfarin, which may need to be administered
quickly, although in some clinical situations a faster-act-
ing anticoagulant such as heparin may be used before
warfarin. Some investigators have advocated using a
loading dose of warfarin and incorporating genotype into
subsequent dose calculations.18 Nonetheless, although
the need for rapid TAT of warfarin genotyping has not
been demonstrated, the demand for clinical laboratories
to provide useful and timely information that impacts
warfarin initiation or dose modification may require as-
says with low failure rates and rapid TAT. As clinical
information grows to accommodate dosing recommen-



























































































06.0 = r06.0 = r
84.0 = r85.0 = r
Figure 1. Comparison of four algorithms for
determining warfarin dosage. Shown is the ac-
tual mean warfarin dose (mg/day) plotted
against the warfarin dose predicted by each of
the dosing algorithms for patients on long-term,
stable warfarin therapy (n 75). Blue diamonds
represent each patient analyzed. Red squares
represent outlier patients with high warfarin
doses not predicted by any of the dosing algo-
rithms. For each graph, solid dark lines represent
the best-fit trendline plotted in Excel using linear
regression and dashed light lines represent the
line of identity. The linear correlation coefficient
(r) for each algorithm is shown.
Table 6. Evaluation of Warfarin Dosage Algorithms
Algorithm
All patients* Less two outliers†
r, r2 Trendline equation r, r2 Trendline equation
Wash U 0.60, 0.36 y  0.9131x  0.9966 0.67, 0.45 y  0.8346x  1.1584
UCSF 0.60, 0.36 y  1.0665x  0.6290 0.67, 0.45 y  0.9725x  0.8346
Louisville 0.58, 0.33 y  0.6985x  1.7400 0.62, 0.38 y  0.6088x  2.0118
Newcastle 0.48, 0.23 y  0.8926x  1.8266 0.54, 0.29 y  0.8147x  1.9115
Comparison of correlation coefficient (r), coefficient of determination (r2), and trendline equations for each algorithm.
* n  75; 81% Caucasian, 19% African-American; 63% male, 37% female.
† n  73; 84% Caucasian, 16% African-American; 64% male, 36% female.
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added genetic information may justify the longer TAT and
cost of the AutoGenomics platform or may dictate devel-
opment of more efficient assays with more complete
genomic information.
Dosing Algorithms
Development of testing in a clinical laboratory includes
not only analytic validation of testing platform, but also
test interpretation and guidance for clinicians. Several
groups have devised dosing algorithms through regres-
sion analysis of the relative effect of CYP2C9 and
VKORC1 variants and various demographic and clinical
factors on warfarin dose. These studies have indicated
that VKORC1 and CYP2C9 genotype may account for up
to 40% of warfarin dose variance, and genotype in addi-
tion to other known factors may account for 50 to 80% of
warfarin dose variance seen in patients with effective
anticoagulation.14–16,19–23 Thus, genetic variability ap-
pears at least as important as other factors that are
currently considered by clinicians when dosing warfarin.
To incorporate warfarin response genotyping at our
institution, we analyzed whether four available dosing
algorithms could accurately predict warfarin dose in a
local patient population. There was a good linear relation-
ship between actual warfarin dose and predicted dose
for each of the algorithms. The UCSF and Wash U algo-
rithms demonstrated the best correlation with actual war-
farin dose, with correlation coefficients (r) of 0.60 in the
total patient population and 0.67 after the removal of two
outlier patients. Both of these algorithms include ethnic-
ity, smoking status, and the presence of a CYP2C9 inhib-
itor as factors whereas the other algorithms do not, which
may be why they performed somewhat better. The New-
castle algorithm performed the least well and tended to
underdose patients, perhaps because it includes height
but not body mass index or weight. Wu and colleagues14
compared several dosing algorithms in a multiethnic
American population and found a similar correlation with
actual warfarin dose as in our study (r  0.64 to 0.68) with
similar worse correlation for the Newcastle algorithm (r 
0.55). Although the Wash U algorithm requires that more
clinical information be gathered on each patient, it did not
perform better than the UCSF algorithm in our population.
The web-based format of the Wash U algorithm is con-
venient and easily accessible, which may make it more
easily adaptable by a wide group of clinicians.
After removal of the two outlier data points, 45% of
warfarin dose variance (r2) was explained by the genetic
and clinical factors included in the Wash U and UCSF
algorithms and less than 40% by the other two algo-
rithms. This is more than the variance in dose that has
been attributed to clinical factors alone, but less than that
reported by other groups. It is unclear why these algo-
rithms explain less of the warfarin dose variance in our
study population than in the populations studied by the
groups that derived the algorithms. There may be factors
unique to different geographic or demographic groups
that affect the efficacy of dosing algorithms derived from
a specific patient population. Wu and colleagues14 pre-
dictably found the best correlation with warfarin dose
using the training set of patients that was used to derive
their own algorithm. Because ours was a small retrospec-
tive analysis, there may have been missing or confound-
ing factors that were not taken into account, or the results
may be skewed by individual patients. This may simply
indicate the better performance of such an approach in a
large group of patients than in an individual patient.
African-American Patients
None of the algorithms predicted warfarin dose very well
in the African-American subgroup, although the data
were skewed by the two outlier patients on high doses of
warfarin. However, even after removal of the two outlier
African-American patients, the predicted warfarin doses
correlated less well with actual warfarin dose in this sub-
group than for the total population. The UCSF algorithm,
which was derived in a multiethnic population, performed
somewhat better in this subgroup, although the number
of patients was too small to make statistically rigorous
conclusions. Only the Wash U and UCSF algorithms in-
corporate ethnicity as a factor. Although part of differ-
ence in warfarin response in different ethnic groups may
be explained by genetic factors, the spectrum of caus-
ative genetic differences is not well understood and there
are almost certainly important environmental factors that
differ between ethnic groups. Accordingly, a recent study
indicated that African-American patients require higher war-
farin maintenance doses even after adjusting for known
clinical and CYP2C9-VKORC1 genetic covariants.24
Because many of the studies of the effect of genotype
on warfarin dose have been performed primarily in Euro-
pean Caucasians, genetic variants more common in
other ethnic groups may be ignored. Thus, CYP2C9 vari-
ants other than 2C9 *2 and *3 that affect warfarin metab-
olism are not incorporated (eg, CYP2C9 *4, *5, *6, and
*11), nor are VKORC1 haplotypes other than those com-
Table 7. Evaluation of Warfarin Dosage Algorithms in African-American Patients
Algorithm
All African-American patients* Less two “outliers†
r, r2 Trendline equation r, r2 Trendline equation
Wash U 0.36, 0.13 y  1.1131x  0.8642 0.52, 0.27 y  0.8447x  1.1604
UCSF 0.33, 0.11 y  1.2723x  0.1863 0.62, 0.38 y  1.2580x  1.0661
Louisville 0.30, 0.09 y  0.4872x  3.7178 0.56, 0.31 y  0.4750x  2.4520
Newcastle 0.34, 0.12 y  0.9184x  3.0793 0.54, 0.29 y  0.7451x  2.5902
Comparison of correlation coefficient (r), coefficient of determination (r2), and trendline equations for each algorithm.
* n  14; 64% male, 36% female.
† n  12; 75% male, 25% female.
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mon in Caucasians, such as H3 to H6 and other rarer
haplotypes that have been described.14 Many of these
variants are more common in African-Americans. The
UCSF multiethnic study, which included Caucasian,
Asian, Hispanic, and African-American populations,
found a significant effect of the VKORC1 SNP 2255(7566)
C, which is seen in haplotypes H3 and H6 to H9 and was
associated with higher doses of warfarin.14 However hap-
lotypes H3 to H6 were grouped together and were not
analyzed individually because of their low frequency.
Further studies are needed in African-American and
other non-European Caucasian populations to under-
stand the relative effect of genetic and other parameters
on warfarin dose requirements.
Warfarin Resistance
The explanation for the high warfarin dose requirement in
the two African-American outlier patients is not known.
VKORC1 SNP analysis indicated that each was heterozy-
gous for VKORC1 H3 or H4, haplotypes reported to be
more common in African-Americans and which may re-
quire higher doses of warfarin.14 However, this is unlikely
to explain the extremely high doses of warfarin required
by these patients. At least six different mutations in the
VKORC1 coding region have been described that are
associated with warfarin resistance, possibly because of
altered binding of warfarin.25–32 Examination of the
VKORC1 coding region for mutations in these patients
was negative. The effect of the novel promoter region
variant found in one of the patients is unknown, although
it is possible that this change could result in higher ex-
pression of VKOR and higher dose requirements.
Currently, the only genetic variants that are included in
the Food and Drug Administration warfarin package in-
sert and incorporated by most of the dosing algorithms
are those associated with increased sensitivity to warfarin
(CYP2C9 *2 and *3, VKORC1 1639/3673 GA). There-
fore patients with VKORC1 variants associated with high
dose requirements of warfarin may not be captured by
current practice. The 1639(3673) SNP, which is seen in
VKORC1 group A haplotypes (H1 and H2) as well as H5,
has consistently been associated with significantly lower
dose requirements of warfarin, possibly because of de-
creased expression of the VKOR protein.1 It is possible
that VKORC1 1639 (or a linked SNP) is the only relevant
functional SNP and explains all of the variability in warfa-
rin response attributable to VKORC1 haplotype. However,
other possible explanations are that the effect of other
variants did not reach statistical significance in some
studies because they were rare in the populations stud-
ied or because they were not analyzed. Wu and col-
leagues14 found that elimination of cases with rare geno-
types improved the correlation between actual warfarin
dose and dose predicted by various algorithms, indicat-
ing that rare variants may have an effect on warfarin dose
that is currently not incorporated in such dosing
algorithms.
The significance of nongroup A VKORC1 haplotypes
requires further investigation. Group B haplotypes (H7 to
H9) have been correlated with higher dose requirements
of warfarin.1,14 Haplotypes H3, H4, and H6, which are
more common in African-Americans, have also been cor-
related with higher doses of warfarin,14 but require further
study in a larger group of patients with these haplotypes.
In addition, patients with certain VKORC1 coding region
mutations may require very high warfarin doses exceed-
ing 10 mg/day.25–32 One of these, the Asp36Tyr mutation,
has been reported to be a common variant in Ashkenazi
and Ethiopian Jews.29,33 We sequenced the VKORC1
coding region for all patients on high doses of warfarin
(10 mg/day) from the 117 patients in the University of
North Carolina study and from a similar study of Brazilian
patients. Although none of the nine University of North
Carolina patients on 10 mg/day of warfarin had coding
region mutations, 2 of 11 Brazilian patients on 10 mg/
day of warfarin had a Val66Met mutation (unpublished
data), which has previously been reported to be associ-
ated with warfarin resistance.26,32 Thus, variants in the
VKOR coding region associated with extreme warfarin
resistance may be common in certain populations, but
are not currently included in any of the available geno-
typing test platforms or dosing algorithms.
Future Directions
The question remains—how will genetic information af-
fecting warfarin response be used clinically? Although
there is a well-documented relationship between specific
CYP2C9 and VKORC1 variants and increased sensitivity
to warfarin, the clinical utility of testing for these variants
in determining optimal warfarin dose has not been well
established. It remains unclear whether dosing algo-
rithms that predict final warfarin dose in patients on stable
long-term therapy will be effective in patients initiating
warfarin therapy. Several clinical trials have been per-
formed to investigate whether incorporation of genotype
in warfarin dosing results in better patient management.
Genotype-guided dosage has been associated with
fewer dosage changes, faster time to target INR, more
time in target INR, and a decrease in out of range INRs in
some studies.12,13,23,34–38 However, overall the results of
these studies have been inconclusive and warfarin geno-
typing has not yet been incorporated into daily practice.
It is unclear whether complicated dosing algorithms will
be widely adopted by the bulk of prescribing physicians.
Perhaps a more practical approach would be for clini-
cians to take genotype information into consideration
along with other factors when dosing warfarin empirically,
for example using an incremental reduction in empirical
starting dose based on the number of sensitivity variants
present. Those patients that will require the greatest dose
modification are those that are homozygous for or have
multiple relevant genetic variants, which represent a
small proportion of the population.
There is still much to be done in the field of pharma-
cogenomics of warfarin dosage. Further studies to eluci-
date the effect of genotypes more common in non-Cau-
casian ethnic groups and to identify other genes that may
have an effect on warfarin response are needed. In ad-
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dition, there is a need for additional clinical trials to
demonstrate whether there exists clear clinical utility of
genotype-guided dosing and if so, the formulation of
easily implementable recommendations for dosing
modification.
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